Latest Ratios: P/E Ratio 21.1x · EV/EBITDA 9.8x · ROE 4.7%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.5B | $1.3B | $2.1B | $3.5B | $2.7B | $4.6B | $3.3B | $3.3B | $1.9B | $1.4B | $1.2B |
| Enterprise Value | $2.3B | $2.1B | $3.0B | $4.4B | $3.7B | $5.2B | $4.0B | $4.1B | $2.3B | $1.9B | $1.7B |
| P/E Ratio → | 21.13 | 26.89 | 16.07 | 53.68 | — | 73.07 | 350.00 | 115.29 | 45.53 | 25.87 | 84.94 |
| P/S Ratio | 1.13 | 0.92 | 1.63 | 2.78 | 2.55 | 4.52 | 3.83 | 3.45 | 2.16 | 1.80 | 1.62 |
| P/B Ratio | 1.55 | 1.22 | 2.21 | 4.14 | 3.57 | 5.81 | 4.65 | 4.64 | 2.80 | 2.27 | 2.13 |
| P/FCF | 11.62 | 8.38 | 13.84 | 32.50 | 229.94 | 47.13 | 64.05 | 43.94 | 31.87 | 27.23 | 52.63 |
| P/OCF | 9.04 | 7.41 | 12.75 | 27.56 | 79.81 | 40.86 | 51.14 | 34.67 | 24.83 | 21.90 | 32.32 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.50 | 2.30 | 3.55 | 3.53 | 5.18 | 4.69 | 4.26 | 2.67 | 2.37 | 2.22 |
| EV / EBITDA | 9.79 | 9.56 | 11.96 | 25.71 | 26.43 | 28.99 | 34.13 | 26.85 | 17.24 | 17.91 | 18.24 |
| EV / EBIT | 16.56 | 20.14 | 15.03 | 36.66 | — | 48.17 | 88.69 | 55.00 | 32.17 | 40.26 | 48.83 |
| EV / FCF | — | 13.64 | 19.56 | 41.59 | 318.53 | 53.98 | 78.60 | 54.16 | 39.42 | 35.84 | 72.27 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8% | 52.8% | 56.1% | 54.3% | 54.6% | 56.2% | 53.4% | 54.9% | 54.6% | 54.1% | 53.5% |
| Operating Margin | 10.3% | 10.3% | 15.3% | 9.7% | 6.7% | 10.9% | 5.3% | 8.3% | 8.3% | 5.9% | 4.9% |
| Net Profit Margin | 3.4% | 3.4% | 10.1% | 5.2% | -7.7% | 6.2% | 1.1% | 3.0% | 4.8% | 7.0% | 1.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.7% | 4.7% | 14.7% | 8.2% | -10.5% | 8.4% | 1.3% | 4.2% | 6.3% | 9.2% | 2.5% |
| ROA | 2.0% | 2.0% | 5.7% | 2.8% | -4.0% | 3.6% | 0.5% | 1.8% | 3.0% | 4.1% | 1.2% |
| ROIC | 5.8% | 5.8% | 8.2% | 5.1% | 3.3% | 5.7% | 2.4% | 4.6% | 4.9% | 3.3% | 3.1% |
| ROCE | 7.0% | 7.0% | 10.0% | 6.0% | 3.9% | 7.0% | 2.9% | 5.7% | 5.9% | 3.9% | 3.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.81 | 0.81 | 0.94 | 1.19 | 1.41 | 0.87 | 1.10 | 1.12 | 0.69 | 0.77 | 0.84 |
| Debt / EBITDA | 3.88 | 3.88 | 3.60 | 5.76 | 7.56 | 3.79 | 6.54 | 5.24 | 3.43 | 4.61 | 5.25 |
| Net Debt / Equity | — | 0.77 | 0.92 | 1.16 | 1.38 | 0.85 | 1.06 | 1.08 | 0.66 | 0.72 | 0.79 |
| Net Debt / EBITDA | 3.69 | 3.69 | 3.50 | 5.62 | 7.35 | 3.68 | 6.31 | 5.07 | 3.30 | 4.30 | 4.96 |
| Debt / FCF | — | 5.26 | 5.73 | 9.10 | 88.59 | 6.85 | 14.54 | 10.22 | 7.55 | 8.61 | 19.64 |
| Interest Coverage | 3.29 | 3.29 | 5.37 | 3.03 | -1.45 | 3.06 | 1.04 | 1.73 | 3.45 | 2.58 | 2.26 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.14 | 2.14 | 2.30 | 1.98 | 1.96 | 2.34 | 2.19 | 2.11 | 2.33 | 2.38 | 2.90 |
| Quick Ratio | 1.01 | 1.01 | 1.05 | 0.96 | 0.84 | 1.16 | 1.17 | 1.24 | 1.37 | 1.44 | 1.71 |
| Cash Ratio | 0.13 | 0.13 | 0.09 | 0.08 | 0.10 | 0.11 | 0.14 | 0.14 | 0.11 | 0.22 | 0.24 |
| Asset Turnover | — | 0.59 | 0.57 | 0.54 | 0.46 | 0.57 | 0.49 | 0.54 | 0.63 | 0.59 | 0.57 |
| Inventory Turnover | 1.83 | 1.83 | 1.66 | 1.79 | 1.43 | 1.91 | 2.06 | 2.61 | 2.53 | 2.58 | 2.61 |
| Days Sales Outstanding | — | 65.81 | 66.39 | 71.04 | 66.80 | 66.41 | 74.97 | 72.27 | 77.09 | 76.56 | 70.87 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.5% | 2.0% | 1.2% | 0.7% | 0.9% | 0.5% | 0.7% | 0.7% | 1.2% | 1.6% | 1.8% |
| Payout Ratio | 52.6% | 52.6% | 18.6% | 38.0% | — | 37.2% | 239.8% | 79.0% | 54.9% | 40.2% | 151.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.7% | 3.7% | 6.2% | 1.9% | — | 1.4% | 0.3% | 0.9% | 2.2% | 3.9% | 1.2% |
| FCF Yield | 8.6% | 11.9% | 7.2% | 3.1% | 0.4% | 2.1% | 1.6% | 2.3% | 3.1% | 3.7% | 1.9% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 2.7% | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.5% | 2.0% | 1.2% | 0.7% | 3.6% | 0.5% | 0.7% | 1.6% | 1.2% | 1.6% | 1.8% |
| Shares Outstanding | — | $31M | $31M | $32M | $30M | $32M | $29M | $29M | $29M | $28M | $28M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CNMD stock.
CONMED Corporation's current P/E ratio is 21.1x. The historical average is 32.8x. This places it at the 40th percentile of its historical range.
CONMED Corporation's current EV/EBITDA is 9.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.7x.
CONMED Corporation's return on equity (ROE) is 4.7%. The historical average is 6.0%.
Based on historical data, CONMED Corporation is trading at a P/E of 21.1x. This is at the 40th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
CONMED Corporation's current dividend yield is 1.54% with a payout ratio of 52.6%.
CONMED Corporation has 52.8% gross margin and 10.3% operating margin. Operating margin between 10-20% is typical for established companies.
CONMED Corporation's Debt/EBITDA ratio is 3.9x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Thin cash buffer against leverage
Metrics are mathematically derived from official filings.
Trailing Multiple Overstates Cost Versus Forward Earnings
Based on the supplied figures, CNMD trades at 34.1x trailing P/E but only 11.3x forward P/E, a gap suggesting reported earnings are depressed by volatile quarterly items rather than reflecting a structurally expensive stock.
The spread between trailing and forward earnings multiples implies the market expects normalization of the earnings swings seen across the last ten quarters, where net margin ranged from 0.8% to 15.5%. A forward EV/EBITDA of 8.6x against a trailing 12.1x points the same direction. Investors should treat the forward multiple as conditional on margin recovery, since the PEG of 0.94 only looks attractive if expected growth materializes given flat recent revenue.
Operating Margin Volatility Obscures Earning Power
According to the reported quarterly figures, CNMD's operating margin swung between 3.6% and 20.7% over the period, with 2026Q3 at 11.1%, indicating that no single quarter reliably represents the company's underlying earning power.
Gross margin has held in a relatively stable 56% to 58% band for most recent quarters, which suggests pricing and product mix are not the primary source of the swings. The variability instead appears to sit in operating expense absorption, implying a normalized operating margin should be estimated across a full cycle rather than read from any single period. Net margin dispersion is wider still, which warrants investigation into non-operating and tax items before capitalizing current earnings.
Returns Decaying Below Historical Peak Levels
Based on reported figures, CNMD's ROIC declined from 2.7% in late 2024 to a range of 0.5% to 2.7% through 2026, while ROE fell from a 5.4% peak to 1.3% in 2026Q1, suggesting returns on capital have not recovered.
Returns sit well below what a company with 56% gross margins would typically generate, pointing to heavy capital intensity or a large asset base diluting profit. Goodwill of $796.9M, roughly 35% of total assets, may depress ROIC by inflating invested capital, which could explain part of the gap versus peers. Investors should assess whether returns are structurally capped or cyclically depressed before assuming a rebound.
Deleveraging Progress Constrained by Coverage
As reported in financial statements, CNMD reduced its D/E from 1.10 to 0.77 over the period, yet interest coverage remained volatile between 1.56x and 7.10x, leaving debt service comfort dependent on the quarter.
Debt fell from $965.9M to $815.9M while equity rose, so the leverage improvement is real but driven partly by retained earnings rather than cash generation alone. Debt-to-EBITDA ratios near 14x to 36x in several quarters suggest the earnings base used to service debt is thin in weaker periods. Refinancing risk cannot be assessed from the supplied data, and investors should monitor coverage trends closely.
Goodwill and Trailing Earnings Distort the Picture
Based on the supplied peer table, CNMD's 8.4% net margin and 9.7% ROIC are not far from MMSI and HOLX, but trail LMAT's 23.1% net margin and 9.7% ROIC on a cash-adjusted basis, with a 0.77 D/E sitting above most peers.
The misapplied metric here is trailing P/E, which is distorted by volatile quarterly net income and the amortization burden tied to $796.9M of goodwill. An EV/EBITDA or free-cash-flow-yield lens, adjusted for acquisition-related amortization, would better reflect earning power. CNMD's gross margin is competitive, so the gap appears to sit below the gross line, consistent with higher operating overhead relative to LMAT; whether this is structural or temporary depends on SG&A intensity, which the supplied data does not confirm.